ReWalk Robotics (NASDAQ:LFWD) Receives “Buy” Rating from HC Wainwright

ReWalk Robotics (NASDAQ:LFWD)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $13.00 target price on the stock.

A number of other research firms have also weighed in on LFWD. Laidlaw initiated coverage on shares of ReWalk Robotics in a report on Monday, February 10th. They set a “buy” rating and a $10.00 price target for the company. Lake Street Capital lowered their target price on ReWalk Robotics from $6.00 to $4.50 and set a “buy” rating for the company in a research note on Thursday, February 20th.

ReWalk Robotics Trading Down 19.6 %

Shares of ReWalk Robotics stock opened at $1.31 on Tuesday. The company has a fifty day moving average price of $1.75 and a 200 day moving average price of $2.23. ReWalk Robotics has a twelve month low of $1.24 and a twelve month high of $6.00. The stock has a market cap of $13.92 million, a price-to-earnings ratio of -0.53 and a beta of 1.73.

ReWalk Robotics (NASDAQ:LFWD) last announced its earnings results on Friday, March 7th. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.53). The company had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $7.30 million. ReWalk Robotics had a negative net margin of 77.21% and a negative return on equity of 43.02%. Analysts forecast that ReWalk Robotics will post -1.78 earnings per share for the current year.

Insider Transactions at ReWalk Robotics

In related news, major shareholder Global Fund Lp Lind II sold 381,676 shares of ReWalk Robotics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $3.36, for a total value of $1,282,431.36. Following the completion of the transaction, the insider now directly owns 1,049,430 shares in the company, valued at approximately $3,526,084.80. This trade represents a 26.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.50% of the company’s stock.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.